Jubilant Ingrevia Ltd. · NSE:JUBLINGREA

Jubilant Ingrevia — Equirus Virtual Investor Conference 2021

32 slides from Jubilant Ingrevia's conference presentation, Sep 22, 2021

  1. Slide 1: Intimation of Investor/Analyst Meetings (filing letter)

    September 22, 2021 BSE Limited National Stock Exchange of India Limited P. J. Towers Exchange Plaza Dalal Street, Bandra Kurla Complex Mumbai - 400 001 Bandra (E), Mumbai - 400 051 Dear Sirs, Sub.: Intimation of Investor/ Analyst Meetings Pursuant to the provisions of Regulation 30 of the Securities

  2. Slide 2: Investors/Analysts participating in the e-Conference

    The following Investors/Analysts shall be participating in the e-Conference: 1 Acuitas Capital 2 Ageas Federal Life Insurance 3 Alchemy Capital 4 Ambit Capital Pvt. Ltd 5 ASK Investments 6 Avendus PMS 7 Baroda Asset Management India Limited 8 BNP Paribas MF 9 BOI AXA 10 Bouyant Capital 11 Capri Glob

  3. Slide 3: Investors/Analysts participating in the e-Conference (continued)

    35 Principal MF 36 Profusion Capital 37 Quest Investments 38 Rare Enterprises 39 Renaissance Investment Managers 40 Roha Asset Managers LLP 41 Safe Enterprise 42 Sage one Investment advisors LLP 43 SBI General Insurance 44 SBI Life Insurance 45 Serum Institute Of India Pvt. Ltd. 46 Siddesh Capital M

  4. Slide 4: Investor Presentation September 2021

    Investor Presentation September- 2021

  5. Slide 5: Disclaimer

    Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f

  6. Slide 6: Jubilant Bhartia Group - Snapshot

    Jubilant Bhartia Group - Snapshot Jubilant Bhartia Group founded by Shyam S Bhartia and Hari S Bhartia, leading industrialists from India Strong presence in diverse sectors like Pharmaceuticals, Life Science Ingredients, Contract Research & Development Services and Therapeutics, Performance Polymers

  7. Slide 7: Jubilant Ingrevia: Glorious Four Decades of Growth

    Jubilant Ingrevia: Glorious Four Decades of Growth 2019: Started new Acetic Anhydride plant, Bharuch SEZ, GJ (50 KTA) Our Journey 10+ years experience 2018: Started Agro Intermediate plant (800 TPA), Bharuch SEZ in Vitamin B3 2017: Certified for Responsible Care (RC) Demerger into 2015: Commissioned

  8. Slide 8: Business Segments & Integrated Operations

    Business Segments & Integrated Operations Integrated Operations… Vertical integration across the value chain enables cost competitive advantage Nutrition &  For Vitamin B3 (Niacinamide & Niacin), 100% in-house sourcing of Beta Picoline Speciality Nutrition & Health Life Science Health Solutions (Ke

  9. Slide 9: Executive Leadership Team

    Executive Leadership Team Rajesh Srivastava Chief Executive Officer & Managing Director 34 years of industry experience Anil Khubchandani R Kumar Chandan Singh President – President – Nutrition & President – Speciality Chemicals Health Solutions Life Science Chemicals 29 years of industry 35 years o

  10. Slide 10: Jubilant Ingrevia: Company Snapshot

    Jubilant Ingrevia: Company Snapshot Revenue Segmentation: By Region Business Segments Leadership Domestic Sales Total 1400+ customers - Amongst top 2 Globally in (Pyridine + Beta) for International • Speciality Chemicals: 420 Speciality Chemicals RoW - Globally # 1 in 11 Pyridine Derivatives 15% Con

  11. Slide 11: Strong Presence in Industry Value Chain

    Strong Presence in Industry Value Chain CDMO Services Commercial Scale Clinical Phase Manufacturing Intermediates / Discovery Process Development API Formulation Phase I / II / III Custom Manufacturing • Route Design, Process • Phase III: 4 Intermediates for Anti-Viral Jubilant Ingrevia’ s familiari

  12. Slide 12: Business Segments

    | Ww | | JUBHANT | INGREVIA Lis rr BUSINESS SEGMENTS

  13. Slide 13: Speciality Chemicals – Segment Snapshot

    Speciality Chemicals – Segment Snapshot Amongst top 2 Region wise Revenue Segmentation (FY’21) 85 Products Globally lowest Key Investment Projects Globally in (Pyridines & Picolines, cost producer of 2 Cyanopyridines, (Pyridine+Beta), - Domestic Sales 1 Pyridine offering Japan,3% Piperidines, Global

  14. Slide 14: Nutrition & Health Solutions – Segment Snapshot

    Nutrition & Health Solutions – Segment Snapshot 5 Nutrition 100% in-house By Region Revenue Segmentation (FY’21) By End use Key Investment Projects Ingredients & Global top 2 in Domestic Sales for Vitamin B3 sourcing of Beta Domestic Consumption 1 2 Cosmetics & Others* Nutrition 18+ branded Picoline

  15. Slide 15: Life Sciences Chemicals – Segment Snapshot

    Life Sciences Chemicals – Segment Snapshot Leadership in Among top Region wise Revenue Segmentation (FY’21) Key Investment Projects 8 Products merchant market suppliers of For Segment For Acetic Anhydride 1 (Acetic Anhydride, Ethyl of Acetic Fuel grade Acetate ,Propionic Domestic Sales for Domestic

  16. Slide 16: Multi Location Manufacturing & Operation Excellence

    Multi Location Manufacturing & Operation Excellence Manufacturing Facilities 463 acres 310 acres 144 acres 109 acres 3.5 acres Gajraula, Uttar Pradesh, Bharuch, Gujarat, India Nira, Maharashtra, India Samlaya, Gujarat, India Ambernath, India Speciality Chemicals, Life Science Chemicals Animal Nutrit

  17. Slide 17: Jubilant Ingrevia: Global Accreditation

    Jubilant Ingrevia: Global Accreditation Select Certifications Gajraula Bharuch Nira Samlaya Ambernath No. of plants 30 5 10 3 2 Responsible Care    RC 14001:2015 ISO      9001:2015 ISO    22000:2005 ISO     14001:2015 ISO     45001:2018 FSSAI     FAMI-QS   HALAL    KOSHER

  18. Slide 18: Business Excellence and Digital Transformation

    Business Excellence and Digital Transformation Belt Competencies (FY’21) Digital Transformation Black Belts: 08 Green Belts: 98 Yellow Belts: 141  Our journey started in 2018 with an objective to improve Business Excellence  Operational efficiency Tools & Processes  Business & Supply chain proces

  19. Slide 19: Research Development & Technology (RDT)

    Research Development & Technology (RDT) 3 RDT centers in Noida, Gajraula and Bharuch 35 Key technology platforms developed & commercialized to global standards. Some are unique: Ammoxidation, Key Grignard etc. Highlights 90 highly qualified scientists (~20 PhDs) > 65 New Products Pipeline for next 5

  20. Slide 20: CSR - Jubilant Bhartia Foundation

    CSR - Jubilant Bhartia Foundation Mission: To develop multi-stakeholder sustainable models to bring about Established ‘social change’ involving knowledge generation & sharing, experiential in 2007 learning & entrepreneurial ecosystem *A sister organization of World Economic Forum*in Partnership with

  21. Slide 21: Sustainability Journey

    Sustainability Journey 2001 2002 2003 2008 2009 2010 2012 2013 2014 2019 Climate Became Jubilant First Product Change UNGC Sustainability Sustainability Sustainability Bhartia Life Cycle 1st EvoVadis EcoVadis Responsible ISO 14000 Mitigation Signatory Goals created Policy Report Foundation Assessmen

  22. Slide 22: #JubilantCares | Our Efforts during Pandemic

    #JubilantCares | Stronger Together | Our Efforts during Pandemic Oxygen Support Ambulances & RTPCR Testing during Crisis Hospital Assistance Isolation Centers Vaccination Drive Camps Provided oxygen cylinders Provided Assistance in Company aided Massive Vaccination Organized RTPCR & concentrators at

  23. Slide 23: Financials

    - Ww JUBHANT ‘ INGREVIA mm er Financials

  24. Slide 24: Jubilant Ingrevia – Q1'FY22 Financial Highlights

    Jubilant Ingrevia – Q1'FY22 Financial Highlights Particulars1 Q1'FY212 Q1'FY22 YoY (%) • Revenue grew by 55% on YoY basis, driven by robust growth in volume and prices. Revenue • Speciality Chemicals revenue grew by 18% YoY driven by volume growth across Speciality Chemicals 257 305 18% product segm

  25. Slide 25: Debt Profile – Q1 FY22

    Debt Profile – Q1 FY22 Particulars1 31/Mar/21 30/Jun/21 Long Term Borrowings 456 227 Short Term Borrowings 92 230 Total 548 457 Cash & Equivalent 117 70 Net Debt 431 386 QoQ change - -10%  Gross Debt reduction of Rs 91 Crore in Q1’FY 22.  Net Debt reduction of Rs 45 Crore in Q1’FY22.  Net Debt to

  26. Slide 26: FY21 Financial Highlights (Pro-forma)

    Jubilant Ingrevia Limited – FY21 Financial Highlights (Pro-forma2) Particulars1 FY20 FY21 YoY (%) • Revenue grew by 10% on YoY basis, driven by growth in volume Revenue Speciality Chemicals 1,104 1,124 2% and pricing both. Nutrition & Health Solutions 537 630 17% • Speciality Chemicals revenue grew

  27. Slide 27: Balance Sheet – Key Parameters/Ratios (Pro-Forma)

    Balance Sheet – Key Parameters/Ratios (Pro-Forma2) Return On Capital Employed (RoCE) Return on Equity Asset / Turnover and Return On Asset (RoA) 1.8x 2.0x 20.2% 16.4% 9.4% (%age) 12.0% (%age) 6.6% FY20 FY21 FY21 FY20 FY21 ROCE % Return on Equity Asset / Turnover ROA % Net Working Capital Operating C

  28. Slide 28: Our Vision, Values, Promise and Philosophy

    Our Vision, Values, Promise and Philosophy OUR PHILOSOPHY Caring Sharing Growing

  29. Slide 29: Thank you

    Thank you

  30. Slide 30: For More Information

    For More Information For Investors: Siddharth Rangnekar CDR India Pavleen Taneja Ph: +91 22 6645 1209 Ph: +91 120 436 1021 E-mail: siddharth@cdr-india.com E-mail: pavleen.taneja@jubl.com For Media: Clayton Dsouza Sudhakar Safaya Madison Public Relations Ph: +91 120 436 1034 E-mail: clayton.dsouza@ma

  31. Slide 31: Appendix

    Appendix

  32. Slide 32: Pro-Forma Income Statement Consolidated – FY21

    Pro-Forma Income Statement Consolidated – FY21 (10 months discontinued operation of LSI segment of Jubilant Pharmova Limited and 2 months Jubilant Ingrevia Limited ) 10M'FY21 2M'FY21 Particulars1 FY20 FY21 YoY (%) Apr'20 to Jan'21 Feb'21 to Mar'21 Revenue from operations a) Sales/Income from operati

Jubilant Ingrevia — Equirus Virtual Investor Conference 2021 on 6ix